AbbVie seeks FDA nod for subcutaneous SKYRIZI induction in Crohn’s disease

The submission is backed by positive results from the Phase 3 AFFIRM study

Raay Neo Pharma launches operations to expand access to quality healthcare across India

Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies

US FDA okays Merck's new once-daily HIV pill

The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir

Pfizer unleashes wave of breakthrough cancer data at ASCO 2026

Pharma giant targets new standards of care

Roche’s MS drug fenebrutinib delivers striking Phase III results by cutting relapse rates by 58%

The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints

Samsung Bioepis unveils promising preclinical data for novel ADC SBE303 at AACR 2026

SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers

K J Somaiya Hospital develops 10-minute tests to bridge India’s haemophilia diagnosis gap

These tests deliver results in 10–15 minutes at a cost of Rs 100–Rs 150, compared to conventional diagnostics which cost up to Rs 15,000

Bayer flags major Phase III results for stroke prevention drug asundexian

The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy

Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies

The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio

Vir Biotechnology advances VIR-5500 into expansion trials in prostate cancer